US FDA task force to weigh disclosure of complete response letters
This article was originally published in Scrip
Executive Summary
The US FDA's transparency task force will hear comments on whether the agency should publicly communicate decisions about pending drug product applications during a November 3rd public meeting. Commenters are asked to discuss whether the agency should disclose receipt of NDAs and BLAs, as well as non-approval decisions and complete response letters.